Tanner Pharma
Tanner Pharma Group, commonly referred to as Tanner Pharma, is a leading provider of global access solutions for patients in need of critical medications. Headquartered in the United States, the company operates extensively across North America, Europe, and Asia, focusing on the pharmaceutical industry. Founded in 2008, Tanner Pharma has achieved significant milestones, including the development of innovative programmes that facilitate access to life-saving therapies. The company specialises in providing comprehensive services such as patient access programmes, clinical trial support, and supply chain management. What sets Tanner Pharma apart is its commitment to ensuring that patients receive the medications they require, regardless of geographical or financial barriers. With a strong market position and a reputation for excellence, Tanner Pharma continues to make a meaningful impact in the healthcare landscape.
DitchCarbon Score
How does Tanner Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tanner Pharma's score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tanner Pharma's reported carbon emissions
Tanner Pharma, headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is a current subsidiary of Tanner Pharma Group, Inc., which may influence its climate commitments and reporting practices. Despite the lack of direct emissions data, Tanner Pharma is part of a broader corporate family that may have established climate initiatives. However, no specific reduction targets or commitments have been documented for Tanner Pharma at this time. The absence of data suggests that the company may still be in the process of developing its climate strategy or reporting framework. As a subsidiary, Tanner Pharma's climate actions may align with those of its parent organisation, but specific details regarding emissions reduction initiatives, Science-Based Targets Initiative (SBTi) commitments, or other climate pledges are not currently available. This context highlights the importance of ongoing efforts within the pharmaceutical industry to address climate change and improve sustainability practices.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tanner Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
